VIKING-MALT-GROUP
30.8.2021 14:43:06 CEST | Business Wire | Press release
Marcin Siemion has decided to leave the Viking Malt Group. He has over many years successfully developed the Viking Malt Polish business and been a key contributor to creating a strong commercial position for Viking Malt Group in the international malting industry. We thank him for his contribution to the company and wish him all the best both privately and professionally. Following this, we would like to announce the following changes in Viking Malt Sales organization:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005352/en/
Malin Andersson has been appointed VP Sales in Viking Malt Group
Malin Andersson will be responsible for the sales strategy and the volume customers. She will become a member of the Group Management Team and in her role help Viking Malt in its mission of providing value-adding malted products to our customers for their success. Malin has been with the company since 1997, successfully leading sales, marketing, customer service and logistics in Viking Malt Sweden as well as had the role of a Site Manager and as latest also the role of Managing Director of Viking Malt Sweden. She has in depth knowledge of the company and the industry with a wide international network in malting and brewing industry. She holds an Executive MBA from Copenhagen Business School.
Annika Wilhelmson will lead the Craft and Partner Sales
At the same time, we have the pleasure to announce that Annika Wilhelmson will be responsible for the Craft and Partner Sales and Marketing. She will continue her work in the Group Management Team and cover Innovation, Quality and CSR in the Vice President role. Annika started with Viking Malt Group in 2017 as VP New Business Development. She holds a doctor´s degree in chemical engineering from Helsinki University of Technology and is specialized in malting. Prior to Viking Malt she has worked at VTT in several roles including senior scientist, project manager and Key Account Manager responsible for sales.
Tomasz Malec appointed Viking Malt Poland Managing Director
VP Supply Chain Tomasz Malec will take over the role of the MD of the Viking Malt Polish entity. He continues in his role as the VP Supply Chain and as the member of the Management Team for the Group.
Before Viking Malt Tomasz Malec worked for Carlsberg for almost twenty years, latest as the VP Production for Carlsberg Poland. Prior to Carlsberg he has worked for Elkometech, Danfoss and Computerland SA as well as Huta Auluminimum Konin SA in different roles. Tomasz holds a degree in engineering from Łódź Technical University, Poland.
“I am delighted to offer these important roles to three of our key leaders. I feel confident that we will continue to serve our customers around the world with high quality malt - and secure that the company with over 130 years of history will stay strong for many years to come“, says CEO Kasper Madsen.
Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark and Lithuania as well as two plants in Poland. The production capacity is 600 000 t/a and the turnover of the group is appr. 250 million euros and the company employ appr. 260 employees. Viking Malt is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
